BIOC

Biocept Inc
0.31
0.00 (0.0%)

Period:

Draw Mode:

Volume 0
Bid Price 0.303
Ask Price 0.38
News -
Day High

Low
0.2358

52 Week Range

High
2.43

Day Low
Company Name Stock Ticker Symbol Market Type
Biocept Inc BIOC NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 0.31 04:00:01
Open Price Low Price High Price Close Price Prev Close
0.31
Trades Volume Avg Volume 52 Week Range
0 0 - 0.2358 - 2.43
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.31 USD

Biocept Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 5.29M 17.06M 17.05M $ 61.25M $ -22.99M -0.19 6.40
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 3.00%

more financials information »

Biocept News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No BIOC Message Board. Create One! See More Posts on BIOC Message Board See More Message Board Posts

Historical BIOC Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.350.350.29110.299236126,705-0.04-11.43%
1 Month0.51980.540.23580.3558997148,954-0.2098-40.36%
3 Months0.550.67210.23580.5047432159,993-0.24-43.64%
6 Months0.910.950.23580.5613954113,618-0.60-65.93%
1 Year2.212.430.23580.8920643103,141-1.90-85.97%
3 Years0.2888.380.23580.96851513,721,3040.0227.64%
5 Years0.29412.150.1410.92350943,543,5690.0165.44%

Biocept Description

Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.